Clinical Report: Impact of Obesity on Polypharmacy Among Older Adults
Overview
This study estimates the contribution of obesity to polypharmacy among older adults in the U.S., revealing that obesity accounts for 14.8% of polypharmacy cases. The findings highlight the significant prevalence of polypharmacy in individuals with obesity, emphasizing the need for targeted interventions.
Background
Polypharmacy is a common issue among older adults, often leading to adverse drug events and diminished quality of life. Obesity is a significant risk factor for many chronic conditions that necessitate polypharmacy. Understanding the relationship between obesity and polypharmacy is crucial for improving medication management in this vulnerable population.
Data Highlights
Measure
Value
Prevalence of Obesity (BMI-defined)
38.7%
Prevalence of Polypharmacy
41.8%
Population Attributable Fraction of Polypharmacy due to BMI-defined Obesity
14.8%
Estimated Older Adults with Polypharmacy Attributable to Obesity
3.3 million
Key Findings
38.7% of older adults in the study had BMI-defined obesity.
Polypharmacy prevalence was significantly higher in those with obesity (51.1%) compared to those without (35.9%).
The population attributable fraction of polypharmacy due to BMI-defined obesity was 14.8%.
Class 2–4 obesity accounted for a PAF of 9.7% of polypharmacy cases.
Waist circumference-defined obesity had a PAF of 24.8% for polypharmacy.
Clinical Implications
Healthcare providers should consider obesity as a modifiable risk factor when managing medications in older adults. Effective weight management strategies may reduce the burden of polypharmacy and improve patient outcomes. Regular medication reviews and adjustments are essential to minimize the risks associated with polypharmacy.
Conclusion
Obesity is a significant contributor to polypharmacy among older adults, with implications for medication management and patient care. Addressing obesity may help mitigate the risks associated with polypharmacy in this population.
